VEGF-Targeted Short Hairpin RNA Inhibits Intraperitoneal Ovarian Cancer Growth in Nude Mice

Abstract

Objective: In this study, we inhibited the expression of VEGF by short hairpin RNA (shRNA) in SKOV3 ovarian cancer cells in vitro and in vivo to explore the antitumor efficacy of shRNA in ovarian cancer cells. Methods: ShRNA targeting VEGF was cloned into pGenesil-2 plasmid vector and then transfected into SKOV3 ovarian cancer cells using liposome. Silencing of VEGF expression was measured by RT-PCR and ELISA assays. Furthermore, the growth inhibition capacity of shRNA on SKOV3 intraperitoneal ovarian carcinomatosis was tested in nude mice. Tumor weight was measured. Microvessel density, number of apoptotic cells and proliferation index in tumor tissues were assessed by CD31, TUNEL and PCNA immunostaining. Results: shRNA targeting VEGF significantly silenced VEGF expression in SKOV3 ovarian cancer cells, confirmed by RT-PCR and ELISA assays (p < 0.05). In vivo, the shRNA reduced tumor weight by ∼60.3% compared with control groups (p < 0.05), accompanied with angiogenesis inhibition (p < 0.01) and apoptosis induction (p < 0.01). Conclusion: Our data indicated that shRNA-mediated silencing of VEGF might be a promising therapeutic strategy against ovarian cancer by reducing angiogenesis and inducing apoptosis.

Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma

“…Tumor volumes were measured every 2 days during treatment duration until animals were sacrificed, and no animal death or signs of possible toxicity were observed during this period (data not shown) [34]. Although the tumors of all mice were approximately equal in initial volumes, significant differences in tumor growth were observed upon treatment with PGAM1-shRNA-a.…”

Proteomics Identification of Annexin A2 as a Key Mediator in the Metastasis and Proangiogenesis of Endometrial Cells in Human Adenomyosis

“…The signals were quantified by QuantityOne software (Bio-Rad) and defined as the ratio of target protein to ␤-actin. ELISA was used to measure VEGF concentration in conditioned medium as described elsewhere (15).…”

“…Pain assessment was done with a 10-point linear analog scale, with 0 representing no pain and 10 representing the worst possible pain. The serum CA12-5 levels of 30 adenomyosis patients (these 30 patients also fell into those 65 patients whose endometrial tissues were further subjected to immunohistochemical analysis) were analyzed using ELISA as described previously (15).…”

A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma

“…In vitro studies demonstrated that siRNA-mediated silencing of oncogenes induces growth arrest and death of tumor cells, indicating their potential therapeutic value [4-7]. Although siRNAs are gene specific, they are not cell/tissue-selective and therefore can not specifically target or accumulate in tumor tissues.…”